Medigene AG (WBO:MDG2) Beta: 1.8811 (As of Jun. 25, 2026)


WBO:MDG2 Medigene AG WBO:MDG2
12 GF Score
Price €0.03
View Full Analysis

What is Medigene AG Beta?

Medigene AG WBO:MDG2 12 Beta is 1.8811 as of Jun. 25, 2026. GuruFocus rates WBO:MDG2 with a GF Score™ of 12/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Medigene AG's Beta is 1.8811.


Medigene AG  (WBO:MDG2) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Medigene AG Beta Related Terms


Medigene AG Beta Historical Data

* Premium members only.

The historical data trend for Medigene AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigene AG Beta Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.62 0.46 0.22 0.24

Medigene AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.22 0.34 0.24 0.34

WBO:MDG2 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Medigene AG's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigene AG Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's Beta distribution charts can be found below:

* The bar in red indicates where Medigene AG's Beta falls into.


WBO:MDG2
12GF Score
Medigene AG WBO:MDG2
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.8811 mean?
Medigene AG (WBO:MDG2) has a Beta of 1.8811 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medigene AG and its competitors.
Is Medigene AG's Beta too high?
Medigene AG's current Beta is 1.8811. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's Beta compare to VRTX and REGN?
Medigene AG's Beta of 1.8811 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medigene AG and its competitors. Medigene AG's current Beta is 1.8811. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (WBO:MDG2) has a current Beta of 1.8811. The current Beta is 1.8811. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Medigene AG (WBO:MDG2), the current Beta is 1.8811 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for WBO:MDG2

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price